We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 3,086

Still No “Newly Acquired Information,” Eliquis Claims Still Preempted
  • Reed Smith LLP
  • USA
  • December 6 2017

The defendants in the Eliquis MDL have turned somewhat of a preemption hat trick. The latest order is In re Eliquis (Apixaban) Prods. Liab. Litig


Dutch Health Council’s proposal of compulsory licensing as solution to high pharma prices
  • Bristows LLP
  • Netherlands, United Kingdom, European Union
  • November 27 2017

Shortly before becoming the new home of the EMA, the Netherlands piqued the interest of the pharma industry with a controversial move on drug pricing


California Passes Two Drug Pricing Transparency Laws
  • Quarles & Brady LLP
  • USA
  • November 20 2017

Last month, California Governor Jerry Brown signed two new bills aimed at curtailing rising prescription drug costs, joining other states like


Washington Healthcare Update - Nov 20, 2017
  • McGuireWoods LLP
  • USA
  • November 20 2017

Reps. David McKinley (R-WV) and Mike Thompson (D-CA) introduced legislation to stop the Centers for Medicare and Medicaid Services (CMS) from cutting


FTC Holds Public Workshop to Consider If Hatch-Waxman Is Working for Prescription Drug Competition
  • Arent Fox LLP
  • USA
  • November 13 2017

On November 8, 2017, the Federal Trade Commission held a workshop entitled, “Understanding Competition in Prescription Drug Markets: Entry and Supply


Commercial Court Refuses Preliminary Injunction Restraining Sale of Generic HIV Drug
  • William Fry
  • Ireland
  • November 10 2017

The Commercial Court has refused an application brought by US-based biopharmaceutical company Gilead Sciences (the plaintiff) for a preliminary


CMA opens four new pharma antitrust probes
  • Slaughter and May
  • United Kingdom
  • November 1 2017

On 13 and 18 October 2017 the Competition and Markets Authority (CMA) announced that it had launched four separate antitrust investigations into


Anticipated Acts of Infringement May Establish Venue for Hatch-Waxman
  • McDermott Will & Emery
  • USA
  • October 31 2017

Addressing venue in the context of Hatch-Waxman litigation, the US District Court for the District of Delaware held that venue is proper in Delaware


Is SB-17 Real Progress on Drug Pricingor an Illusion?
  • Manatt Phelps & Phillips LLP
  • USA
  • October 24 2017

On September 13, 2017, the California State Senate followed the Assembly in passing SB-17 to increase the transparency around brand-name and generic


Healthcare Post-Mortem: Medical Industry Continues to be High-Value Target for FCA Enforcement
  • Vinson & Elkins LLP
  • USA
  • October 18 2017

Last week we gave you the bottom line of how much DOJ (and relators) recovered in FY 2017. As we promised, we are doing a series of sector-specific